title: Efficiency of second pegylated interferon and ribavirin combination treatment for the relapsed hepatitis C virus infection in low-income countries.
authors.affiliation: aDepartment of Infectious Diseases and Clinical Microbiology, Medical Faculty, Bezmialem Vakif University bDepartment of Infectious Diseases and Clinical Microbiology, Medical Faculty, Medipol University cIstanbul Training and Research Hospital, Clinic of Infectious Diseases and Clinical Microbiology dDepartment of Infectious Diseases and Clinical Microbiology, Medical Faculty, Medeniyet University, Istanbul, Turkey.
authors.forename: Bahadir
authors.initials: B
authors.lastname: Ceylan
authors.forename: Ferhat
authors.initials: F
authors.lastname: Arslan
authors.forename: Ferhat
authors.initials: F
authors.lastname: Aslan
authors.forename: Cem
authors.initials: C
authors.lastname: Yardimci
authors.forename: Muzaffer
authors.initials: M
authors.lastname: Fincanci
authors.forename: Nail
authors.initials: N
authors.lastname: Özgüneş
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011203:Poverty; D012367:RNA, Viral / Q000097:blood; D012008:Recurrence; D019233:Retreatment; D012254:Ribavirin / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014421:Turkey; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D012367:RNA, Viral; D012254:Ribavirin; D007372:Interferons